Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Sangamo Therapeutics clinical trials
Also known as Sangamo BioSciences.
The registry lists 29 studies whose lead sponsor is Sangamo Therapeutics or one of 1 company grouped under it. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 20, 2026.
Keep track of what changes. Save the Sangamo Therapeutics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Sangamo Therapeutics.
- Sangamo Therapeutics28 studiesSame company
Something wrong?
- 1 study →
Studies
Recruiting first, then most recently updated. Showing 29 of 29.
- Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)RecruitingNCT06980948Phase 1/2
- Long-Term Follow-up of Subjects Who Were Treated With ST-920Active, not recruitingNCT05039866
- Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIXTerminatedNCT04628871
- Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant RecipientsCompletedNCT04817774Phase 1/2
- Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)CompletedNCT04046224Phase 1/2
- Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)Active, not recruitingNCT05987527
- Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.Active, not recruitingNCT05145062
- A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell DiseaseCompletedNCT03653247Phase 1/2
- Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia BTerminatedNCT02695160Phase 1
- Long-term Follow-up of HIV Subjects Exposed to SB-728-T or SB-728mR-TTerminatedNCT04201782
- A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)CompletedNCT03432364Phase 1/2
- Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS ITerminatedNCT02702115Phase 1/2
- CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT00087789Phase 1
- Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's DiseaseCompletedNCT00252850Phase 1
- Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's DiseaseCompletedNCT00400634Phase 2
- Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS IITerminatedNCT03041324Phase 1/2
- Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT01079325Phase 2
- Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-TCompletedNCT01543152Phase 1/2
- Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAARTCompletedNCT02225665Phase 1/2
- Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT00876863Phase 2
- Safety and Efficacy of CERE-120 in Subjects With Parkinson's DiseaseCompletedNCT00985517Phase 1/2
- Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected SubjectsCompletedNCT01252641Phase 1/2
- Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's DiseaseTerminatedNCT02327221Phase 2
Sponsor listed in the registry: TxCell · First submitted before TxCell became part of Sangamo Therapeutics
- Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected PatientsCompletedNCT01044654Phase 1
- Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT00476931Phase 2
- Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT00748501Phase 2
- Clinical Trial of SB-509 in Subjects With Diabetic NeuropathyCompletedNCT00406458Phase 2
- Stem Cell Mobilization in Diabetic Neuropathy Subjects Receiving SB-509CompletedNCT00665145Phase 2
- Clinical Trial of SB-509-0401 in Subjects With Diabetic NeuropathyCompletedNCT00110500Phase 1